|
US4234571A
(en)
*
|
1979-06-11 |
1980-11-18 |
Syntex (U.S.A.) Inc. |
Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
|
|
DE3411224A1
(de)
*
|
1984-03-27 |
1985-10-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
|
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
|
US4705778A
(en)
*
|
1985-10-22 |
1987-11-10 |
Sri International |
Orally active LHRH analogs
|
|
JPH0284272U
(OSRAM)
*
|
1988-12-20 |
1990-06-29 |
|
|
|
JP2672677B2
(ja)
*
|
1989-02-09 |
1997-11-05 |
タツプ・フアーマシユーテイカルズ・インコーポレイテツド |
Ｌｈｒｈ同族体
|
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
|
NZ244499A
(en)
*
|
1989-03-10 |
1999-05-28 |
Endorecherche Inc |
Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth
|
|
DE69032648T2
(de)
*
|
1989-07-07 |
1999-04-08 |
Endorecherche Inc., Ste-Foy, Quebec |
Androgenderivate zur Hemming der Aktivität der Sexualsteroide
|
|
DE69034035T2
(de)
*
|
1989-07-07 |
2004-01-22 |
Endorecherche Inc., Ste-Foy |
Methode zur behandlung androgenbedingter krankheiten
|
|
GB9112859D0
(en)
*
|
1991-06-14 |
1991-07-31 |
Ici Plc |
Peptide process
|
|
AU4258493A
(en)
*
|
1992-05-21 |
1993-12-13 |
Endorecherche Inc. |
Inhibitors of testosterone 5alpha-reductase activity
|
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
CA2192773C
(en)
|
1995-12-15 |
2008-09-23 |
Hiroaki Okada |
Production of sustained-release preparation for injection
|
|
CA2192782C
(en)
|
1995-12-15 |
2008-10-14 |
Nobuyuki Takechi |
Production of microspheres
|
|
EP1008656A4
(en)
|
1996-06-13 |
2000-09-20 |
Itoham Foods Inc |
METHOD FOR PRODUCING LH-RH DERIVATIVES
|
|
US6051558A
(en)
*
|
1997-05-28 |
2000-04-18 |
Southern Biosystems, Inc. |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US20060025328A1
(en)
*
|
1997-05-28 |
2006-02-02 |
Burns Patrick J |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US6242421B1
(en)
|
1997-11-06 |
2001-06-05 |
Richard Lloyd Bowen |
Methods for preventing and treating Alzheimer's disease
|
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
|
ES2154590B1
(es)
|
1999-05-20 |
2001-11-01 |
Lipotec Sa |
Procedimiento de sintesis de peptidos en fase solida
|
|
AR023940A1
(es)
|
2000-05-03 |
2002-09-04 |
Eriochem Sa |
Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
|
|
DE10032256C2
(de)
*
|
2000-07-03 |
2003-06-05 |
Infineon Technologies Ag |
Chip-ID-Register-Anordnung
|
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
|
PT2269603E
(pt)
|
2001-02-19 |
2015-09-09 |
Novartis Ag |
Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
|
|
PT1392313E
(pt)
|
2001-05-16 |
2007-07-17 |
Novartis Ag |
Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
|
|
US20060287282A1
(en)
*
|
2001-06-25 |
2006-12-21 |
Steiner Mitchell S |
Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
|
|
EP1444988A4
(en)
|
2001-11-13 |
2007-04-25 |
Takeda Pharmaceutical |
CANCER AGENT
|
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
|
US20030144203A1
(en)
*
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
PL372103A1
(en)
|
2002-05-16 |
2005-07-11 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
|
SI1575569T1
(sl)
|
2002-12-13 |
2010-12-31 |
Durect Corp |
Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
|
|
CA2532965C
(en)
|
2003-07-22 |
2013-05-14 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
|
GB0320806D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
|
WO2005097791A1
(en)
|
2004-04-07 |
2005-10-20 |
Novartis Ag |
Inhibitors of iap
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
JP4346650B2
(ja)
*
|
2004-06-25 |
2009-10-21 |
武田薬品工業株式会社 |
メタスチン誘導体およびその用途
|
|
SI2767292T1
(sl)
|
2004-09-17 |
2017-01-31 |
Durect Corporation |
Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
|
|
GB0425854D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Astrazeneca Ab |
Therapeutic treatment
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
RU2436575C2
(ru)
*
|
2005-01-21 |
2011-12-20 |
Астекс Терапьютикс Лимитед |
Соединения для использования в фармацевтике
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
KR101346886B1
(ko)
|
2005-01-21 |
2014-01-02 |
아스텍스 테라퓨틱스 리미티드 |
제약 화합물
|
|
EP2119725A1
(en)
*
|
2005-05-03 |
2009-11-18 |
Novetide Ltd. |
Methods for the production of leuprolide
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
|
KR20080054417A
(ko)
|
2005-09-27 |
2008-06-17 |
노파르티스 아게 |
카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
EP2026800A1
(en)
|
2006-05-09 |
2009-02-25 |
Novartis AG |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
|
BRPI0717564A2
(pt)
|
2006-09-29 |
2013-10-22 |
Novartis Ag |
Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
|
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
EP2117521B1
(en)
|
2006-11-03 |
2012-06-27 |
Durect Corporation |
Transdermal delivery systems comprising bupivacaine
|
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
|
EP2067471B1
(en)
*
|
2007-12-06 |
2018-02-14 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
|
WO2009118292A1
(en)
|
2008-03-24 |
2009-10-01 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
|
EP2260020B1
(en)
|
2008-03-26 |
2014-07-23 |
Novartis AG |
Hydroxamate-based inhibitors of deacetylases b
|
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
|
JP2012510442A
(ja)
*
|
2008-11-28 |
2012-05-10 |
ノバルティス アーゲー |
Ｈｓｐ９０阻害剤の組合せ
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
DK2391366T3
(da)
|
2009-01-29 |
2013-01-07 |
Novartis Ag |
Substituerede benzimidazoler til behandling af astrocytomer
|
|
UA105794C2
(uk)
|
2009-06-26 |
2014-06-25 |
Новартіс Аг |
1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
JP5781510B2
(ja)
|
2009-08-12 |
2015-09-24 |
ノバルティス アーゲー |
ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
|
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
|
EA201200321A1
(ru)
|
2009-08-26 |
2012-09-28 |
Новартис Аг |
Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
|
|
EA201200471A1
(ru)
|
2009-09-10 |
2012-10-30 |
Новартис Аг |
Простые эфирные производные бициклических гетероарилов
|
|
JP5466767B2
(ja)
|
2009-11-04 |
2014-04-09 |
ノバルティス アーゲー |
Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
|
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
|
ES2484171T3
(es)
|
2009-12-08 |
2014-08-11 |
Novartis Ag |
Derivados de sulfonamidas heterocíclicas
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
WO2011156908A1
(en)
|
2010-06-16 |
2011-12-22 |
Endorecherche, Inc. |
Methods of treating or preventing estrogen-related diseases
|
|
EP2582680A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
|
US20130085161A1
(en)
|
2010-06-17 |
2013-04-04 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
JP2013537210A
(ja)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
|
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
US20130338152A1
(en)
|
2011-03-08 |
2013-12-19 |
Irm Llc |
Fluorophenyl bicyclic heteroaryl compounds
|
|
EA023064B1
(ru)
|
2011-04-28 |
2016-04-29 |
Новартис Аг |
ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
|
|
EP2709991B1
(en)
|
2011-05-16 |
2020-09-02 |
Genzyme Corporation |
Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia
|
|
MX2013014398A
(es)
|
2011-06-09 |
2014-03-21 |
Novartis Ag |
Derivados de sulfonamida heterociclicos.
|
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
|
PH12013502524A1
(en)
|
2011-06-27 |
2014-01-27 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
WO2013038362A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
|
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
|
PE20141598A1
(es)
|
2011-12-22 |
2014-11-14 |
Novartis Ag |
Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
|
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
|
CA2859873A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
AU2012355624A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
EA201491264A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
|
|
AU2012355613A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
AU2012355619A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
|
UY34807A
(es)
|
2012-05-16 |
2013-12-31 |
Novartis Ag |
Derivados monocíclicos de heteroarilcicloalquil- diamina
|
|
WO2013175417A1
(en)
|
2012-05-24 |
2013-11-28 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
|
WO2013188763A1
(en)
|
2012-06-15 |
2013-12-19 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
|
EP2882747B1
(en)
|
2012-08-13 |
2016-04-27 |
Novartis AG |
Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk)
|
|
MX2015003959A
(es)
|
2012-10-02 |
2015-11-16 |
Epitherapeutics Aps |
Inhibidores de histona demetilasas.
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
ES2670864T3
(es)
|
2013-02-27 |
2018-06-01 |
Gilead Sciences, Inc. |
Inhibidores de histonas desmetilasas
|
|
CA2905131A1
(en)
|
2013-03-15 |
2014-09-18 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
CA2918938C
(en)
|
2013-09-22 |
2021-05-18 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
RU2020121929A
(ru)
|
2014-01-15 |
2020-07-13 |
Новартис Аг |
Фармацевтические комбинации
|
|
WO2015148868A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
AR099890A1
(es)
|
2014-03-31 |
2016-08-24 |
Epitherapeutics Aps |
Inhibidores de histona demetilasas
|
|
WO2015153345A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
|
MX2017002451A
(es)
|
2014-08-27 |
2017-05-23 |
Gilead Sciences Inc |
Compuestos y metodos para inhibir histona desmetilasas.
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
JP7258561B2
(ja)
|
2016-07-06 |
2023-04-17 |
オリエント ファーマ シーオー．，エルティーディー． |
薬物組成物、バリヤー層及び薬物層を有している経口投与形態
|
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
|
WO2019119486A1
(zh)
|
2017-12-21 |
2019-06-27 |
中国科学院合肥物质科学研究院 |
一类嘧啶类衍生物激酶抑制剂
|
|
WO2019143874A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
CA3155594C
(en)
|
2019-09-26 |
2025-06-17 |
S I S Shulov Innovative Science Ltd |
Topical anti-aging compositions containing a tetrapeptide
|
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
|
KR20220140711A
(ko)
|
2020-01-13 |
2022-10-18 |
듀렉트 코퍼레이션 |
불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
|
|
KR20230145053A
(ko)
|
2021-01-12 |
2023-10-17 |
듀렉트 코퍼레이션 |
지속 방출 약물 전달 시스템 및 관련 방법
|